Influencers are NOT KOLs. Know your Needs! 0 days ago Influencers are NOT KOLs. We discuss using key opinion leaders (KOLs) and influencers in pharmaceutical and medical device marketing. Key Takeaways:
FDA Concerns About AI's impact on Good Clinical Practices 6 days ago Today we're delving into the evolving role of artificial intelligence (AI) in drug development and clinical trial design. We’ll explore the key conc
Are CROs Losing Relevance in the Age of DCTs? 7 days ago In this episode, Isaac Rodriguez-Chavez and I discuss the impact of clinical trials DCTs on sponsor relationships, CROs, and industry dynamics with th
FDA Concerns About AI's impact on Good Clinical Practices 6 days ago Today we're delving into the evolving role of artificial intelligence (AI) in drug development and clinical trial design. We’ll explore the key conc
Tech Transfer’s Role in Clinical trial agreements 21 days ago In this episode, we are joined by Istvan Fekete to have a discussion over tech transfer offices, IP, and more. The video explains what tech transfer o
Analyzing the Publication Rights Clause in CTAs 1 months ago Today's discussion revolves around the legal clauses found in clinical trials, with a focus on Article 8, the Publication Rights Clause. The followi
McKinsey’s 2030 vision: A challenge for medical affairs 6 months ago McKinsey’s vision for Medical Affairs in 2030 envisions profound integration of digital tools, analytical innovation, evidence generation, and leade
Medical Affairs Strategic Thinking & Changing Landscape | Darshan Talks In this episode of the DarshanTalks Podcast, host Darshan Kulkarni Pharm.D, MS, Esq. welcomes Biopharma Medical Affairs expert, Irene von Hennigs, Pha
Little-known Facts about Non Therapeutic Uses of Drugs and Devices | Patti Zettler In today’s episode of DarshanTalks Podcast, host Darshan Kulkarni welcomes guest Patti Zettler to talk about the non-therapeutic uses of drugs and d